Collegium Pharmaceutical Stock Price, News & Analysis (NASDAQ:COLL)

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Collegium Pharmaceutical Inc (NASDAQ:COLL) issued its earnings results on Wednesday, August, 7th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.19) by $0.05. The specialty pharmaceutical company had revenue of $75.04 million for the quarter, compared to analysts' expectations of $75.77 million. Collegium Pharmaceutical had a negative net margin of 7.45% and a negative return on equity of 26.10%. The firm's revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.40) earnings per share. View Collegium Pharmaceutical's Earnings History.

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Collegium Pharmaceutical.

6 analysts have issued 12 month price objectives for Collegium Pharmaceutical's shares. Their predictions range from $22.00 to $33.00. On average, they expect Collegium Pharmaceutical's stock price to reach $26.20 in the next year. This suggests a possible upside of 120.4% from the stock's current price. View Analyst Price Targets for Collegium Pharmaceutical.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Collegium Pharmaceutical.

Media stories about COLL stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Collegium Pharmaceutical earned a coverage optimism score of -3.2 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Collegium Pharmaceutical.

Collegium Pharmaceutical saw a drop in short interest in the month of September. As of September 15th, there was short interest totalling 2,810,000 shares, a drop of 7.0% from the August 15th total of 3,020,000 shares. Based on an average daily volume of 275,600 shares, the days-to-cover ratio is currently 10.2 days. Approximately 10.1% of the shares of the stock are sold short. View Collegium Pharmaceutical's Current Options Chain.

Some companies that are related to Collegium Pharmaceutical include Tricida (TCDA), Pacira Biosciences (PCRX), Insmed (INSM), Aimmune Therapeutics (AIMT), Heron Therapeutics (HRTX), Nabriva Therapeutics (NBRV), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Eidos Therapeutics (EIDX), Madrigal Pharmaceuticals (MDGL), Opko Health (OPK), BELLUS Health (BLUSF), Turning Point Therapeutics (TPTX), Enanta Pharmaceuticals (ENTA) and Radius Health (RDUS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), Celgene (CELG), NVIDIA (NVDA), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Synergy Pharmaceuticals (SGYP), GW Pharmaceuticals PLC- (GWPH), Micron Technology (MU), Bausch Health Companies (BHC) and Advanced Micro Devices (AMD).

(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Collegium Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Campbell & CO Investment Adviser LLC (0.03%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Longitude Capital Partners, Ll, Michael Thomas Heffernan, Paul Brannelly and Scott Dreyer. View Institutional Ownership Trends for Collegium Pharmaceutical.

COLL stock was acquired by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Collegium Pharmaceutical.

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of COLL stock can currently be purchased for approximately $11.89.

Collegium Pharmaceutical has a market capitalization of $397.96 million and generates $280.41 million in revenue each year. The specialty pharmaceutical company earns $-39,130,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.View Additional Information About Collegium Pharmaceutical.

The official website for Collegium Pharmaceutical is http://www.collegiumpharma.com/.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.